For personal use only

Transcription

1

2 dorsavi s wearable technology measures quality of movement in OHS, Clinical and Elite Sports environments. We provide objective, easy to interpret data that creates actionable results for workers, patients and athletes. dorsavi Ltd (ASX: DVL) listed in Dec 2013 Multiple patents involving movement analysis FDA Clearance, CE Mark (EU) and TGA (Aust) Approved and selling in US, Europe and Australia Strong sales momentum with major brands 2

3 Points of Differentiation 6 patents using sensors and analysing human movement Develop own hardware, firmware, software Sensor system best in class in terms of accuracy 2 to 8 sensors with automated analysis and reporting FDA clearance for medical grade wearable First reference to normative low back data and posture measure Clinical Trial data showing exceptional low back treatment results First mover advantage OHS, Clinical and Sports markets 3

4 Financial Overview dorsavi Ltd (ASX : DVL) Share price $0.35 Shares on issue 149,914,616 Market capitalisation $52.5 million * H1 2016* Revenue** 398, ,380 1,358,218 1,291,989* EBITDA (2,148,749) (3,852,593) (8,684,709) (3,292,932) Loss from continuing operations Cash position (1,659,235) (3,562,024) (8,036,161) (3,109,328) $13.97M $5.74M $8.92M* * Unaudited ** Excludes Interest Earned and Grant Income *Unaudited Results 4

5 Financial Overview Comparison (H1 FY15 vs H1FY16) Revenue 110% Increased scale and size of OHS clients Repeat OHS deals with major clients Recent launch of OHS in US & UK Increase in clinical trial sites via large US & UK deals Device Sales 114% Large Chains coming on board Strong word of mouth referrals Improved software and usability Expenses 8% Reduction in operating costs Outsourcing of OHS model Data analysis efficiency 5

6 Revenue Growth Jurisdictional Comparison

7 Highlights from H1 ViSafe (OHS) Launched OHS product into the UK and the US New contracts with major OHS clients in UK & US (Toyota, Jaguar, TFL, Heathrow) Repeat & large scale OHS deals contracts (TFL, Crown and Monash/Allianz) ViMove (Clinical) Beachhead Clients UK: YourPhysioPlan US: Physio Associates (540 sites) Clinical trial publication using ViMove shows 40% reduction in chronic low back pain 70% improvement in function and Health economic paper to follow ViPerform (Sport) Multiple US elite sports (LA Lakers, New England Patriots, Golden State Warriors) Initial College sites (Ohio State & Marquette) 7

8 Providing the Movement Metrics needed for Decision Making in OHS Work injuries cost $250B p.a. (US) Unique movement data determines high risk activities Interventions involving: Job assessment, Equip change, Pre employ screen Better decisions based on fact, not opinion Large untapped market Offering resonates with decision makers Market characterized by 1000 s of corporates & insurers 8

9 Making a huge commercial difference to our clients Case study from large organisation Used dorsavi sensors to identify risk & plan changes Third party pre employment screening Consumable revenue from 300+ screenings to dorsavi Optimised training protocol benchmarking Months Number of of employment Injuries Vs Tenure prior of to Employees first injury Months Number of of employment Injuries Vs Tenure prior of to Employees first injury 72 injuries Q injury Q by Customised Screening Injuries 1 Injury Employees suited to task Improved work design Prior to dorsavi intervention After dorsavi intervention 9

10 RISK CLAIMS 10

11 RISK CLAIMS 11

12 RISK CLAIMS P Foundation Project feeds other commercial projects

13 Achieving the Triple Bottom Line with large corporates 1. Reduce Costs & Injuries 2. Improve Safety Culture 3. Improve Productivity 13

14 Effective healthcare at lower cost $560B Health care reform in the US demands low cost alternatives Opiates kill more people than MVAs in US $309B Positive Clinical Trial data treating low back pain $243B $560B market with significant barriers for competitors $188B FDA / CE / TGA Clearance Momentum building from word of mouth Diabetes Cancer Heart Disease Chronic Pain 14

15 45% Reduction in Pain Compelling Clinical Data in Chronic Low Back Pain * Peer reviewed publication in May 2015 BMC Musculo Skeletal Journal, (Assc Prof Peter Kent, Denmark) A multi-center, cluster randomized, placebocontrolled trial 73% Increase in Function (P<0.001) Clinical trial undertaken at 8 sites including the Austin and Epworth Hospitals. 112 subject Randomised Controlled Trial (RCT) with 54 control and 58 intervention subjects. * Significant and sustained results at 52 weeks for both reduced pain and improved function. (P<0.001) *QVAS Quadruple Visual Analogue Scale (a pain scale) **PSFS Patient Specific Functional Scale 52 weeks

16 Fundamentally Changing Clinical Practice Goal: Be the standard of care in clinical work dorsavi well positioned: Regulatory clearance Very positive Clinical Trial data Clear reimbursement plan Payers want a proven treatment protocol Payers need to know treatment is working 16

17 Used across all aspects of patient management Assessment: FDA Cleared Advice: Educational & engaging to empower patient Training: Movement re-education with live data feedback Exercise: Stand alone patient driven exercises with live visual biofeedback 17

18 Fully Functional across 80% of clinical sessions Hamstring Running Knee Control Core Control 18

19 Large Scale Clinical Chains UK distribution deal 100 physio clinics in UK and Ireland with plans to expand rapidly Three year deal includes minimum sales targets of 100, 300 and 600 ViMove units Potential deal valued of AU$9M over the three years (if minimum targets achieved). US Physio Chain 20 physio clinics in US within Physio Associates (540 clinics in total) Initial pilot to optimise offering within US clinical market Specific applications relate to knee injury prevention and running module 19

20 Global penetration > 240 devices in market 130 devices (Aust) 55 devices (Europe) 55 devices (USA) Aust 24,000 Physios (0.5% Penetration) UK 48,000 Physios USA 284,000 Physical Therapists Immediate target market: > 350,000 Physios (with a greater number of Doctors) Annuity model (clinics pay $5,000 7,500 p.a. per unit) with 87% retention 20

21 Elite Sports - $160B Market Sports providing great PR and validation Drives new cutting edge innovation (clinical and OHS relevant) A number of commercial injury prevention projects Unique insights provided to world s biggest sporting brands Leverage into consumer wearables market with major players 21

22 Used for injury prevention and assessment at the highest level Hamstring AFL, NFL, NBA, EPL Return to play decisions - AFL, NFL, NBA Knee AFL, NFL, NBA, EPL Running EPL, AFL, NFL, NBA 22

23 Exciting Tech Development Schedule dorsavi through the Continuum of Care OHS Clinical Sport Prevention Early Management Markers for Surgery Dynamic Surgery Waiting List Alignment during Surgery Post surgery acute rehab Long term monitoring and support Multiple options for Professional Consumer products Significant interest and vision from large corporates in each jurisdiction 23

24 Synergy between OHS and Clinical market 24

25 Upcoming Milestones/Newsflow Long term OHS contracts with major corporates (US, UK & Aust) Repeat deals with major insurers Recruit first patient into US low back registry Publication of Health Economic evaluation from large clinical trial Multiple US elite sports across different codes and colleges Launch App based mini sensor into OHS & Clinical market Develop consumer product in alliance with partner 25

26 Appendix 26

27 Board and Senior Management Chairman Herb Elliott Non Executive Director Greg Tweedly Non Executive Director Michael Panaccio Non Executive Director Ash Attia Director & CEO Andrew Ronchi CFO Damian Connellan CIO Meagan Blackburn CMO Dave Wildermuth Head of Sales and Operations Australia Matt May Head of Sales and Operations Europe Zoë Whyatt Head of Sales and Operations US Mark Heaysman 27